ClinicalTrials.gg
CompletedNCT03940742Updated Mar 24, 2023Results posted

A Study of Tirzepatide in Participants With Impaired Liver Function

A Phase 1 interventional study of Tirzepatide in Hepatic Insufficiency, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
7th of 12
32 · median 34
Started
2019
the only one that year
Phase 1
12 of 12
2 open now
Registered
5th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 7th largest by enrollment, is the only one that started in 2019, is one of 12 in phase 1, and was the 5th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Hepatic Insufficiency studies recruiting now, 3 (30%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Women of are excluded from the study.
  • Women not of childbearing potential may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or
  • Are between the (BMI) of 19.0 and 40.0 kilograms per meter squared (kg/m²), inclusive, at screening

Healthy Participants:

  • Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal liver function

Participants with Impaired Liver Function:

  • Males or females with chronic mild, moderate and severe liver impairment, assessed by scoring
  • Have type 2 diabetes mellitus (T2DM) controlled with diet or exercise alone or on stable doses of metformin for at least 8 weeks
  • Have a (HbA1c) ≥6.0% and ≤11.0% at screening

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Have known allergies to tirzepatide or related compounds
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or GI disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors

Participants with Impaired Liver Function:

  • Have \<8.5 grams per deciliter (g/dL)
  • Have kidney function that is significantly impaired at screening
  • Have taken any glucose-lowering medications other than metformin, including insulin, in the past 3 months before screening
  • Have brain function impaired significantly due to liver condition
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Normal Hepatic Function

    Participants with normal hepatic function received single subcutaneous dose of 5 milligrams (mg) tirzepatide.

    Drug: Tirzepatide

  • Experimental
    Mild Hepatic Impairment

    Participants with mild hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

    Drug: Tirzepatide

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

    Drug: Tirzepatide

  • Experimental
    Severe Hepatic Impairment

    Participants with severe hepatic impairment received single subcutaneous dose of 5 mg tirzepatide.

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide

    Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of Tirzepatide.

    Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose

  2. PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

    PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.

    Time frame: Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose

07

Results

Posted Mar 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneControl (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Started13667
Received at least one dose of study drug13667
Completed13666
Not completed0001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryPharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide

Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC\[0-∞\]) of Tirzepatide.

Time frame:
Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide
nanogram*hour per milliliter (ng*h/mL)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics (PK): Area Under The Drug Concentration-Time Curve From Zero To Infinity (AUC[0-∞]) of Tirzepatide84300 ± 28102000 ± 1682000 ± 2977000 ± 33
Statistical analysis
  • Control (Normal Hepatic Function) vs Mild Hepatic Impairment · Ratio of geometric least squares mean: 1.08 · 90% CI 0.879 to 1.32
  • Control (Normal Hepatic Function) vs Moderate Hepatic Impairment · Ratio of geometric least squares mean: 0.960 · 90% CI 0.790 to 1.17
  • Control (Normal Hepatic Function) vs Severe Hepatic Impairment · Ratio of geometric least squares mean: 0.852 · 90% CI 0.699 to 1.04
PrimaryPK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide.

Time frame:
Predose, 8, 12, 24, 48, 72, 96, 168 and 336 post dose
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
ng/mLControl (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
PK: Maximum Observed Drug Concentration (Cmax) of Tirzepatide510 ± 28509 ± 18516 ± 44521 ± 23
Statistical analysis
  • Control (Normal Hepatic Function) vs Mild Hepatic Impairment · Ratio of geometric least squares mean: 0.916 · 90% CI 0.726 to 1.16
  • Control (Normal Hepatic Function) vs Moderate Hepatic Impairment · Ratio of geometric least squares mean: 1.00 · 90% CI 0.802 to 1.25
  • Control (Normal Hepatic Function) vs Severe Hepatic Impairment · Ratio of geometric least squares mean: 0.972 · 90% CI 0.784 to 1.21

Adverse events

Collected over Baseline to Study Completion (Up to 14 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control (Normal Hepatic Function)0/13 (0%)0/13 (0%)4/13 (30.8%)
Mild Hepatic Impairment0/6 (0%)0/6 (0%)2/6 (33.3%)
Moderate Hepatic Impairment0/6 (0%)0/6 (0%)2/6 (33.3%)
Severe Hepatic Impairment0/7 (0%)1/7 (14.3%)2/7 (28.6%)
Most frequent serious events
Most frequent serious events
EventControl (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Hepatic encephalopathyNervous system disorders0/130/60/61/7
Most frequent other events
Showing 10 of 14
Most frequent other events
EventControl (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
NauseaGastrointestinal disorders3/132/60/61/7
VomitingGastrointestinal disorders0/131/62/61/7
Abdominal distensionGastrointestinal disorders0/130/61/60/7
DyspepsiaGastrointestinal disorders0/131/60/60/7
FlatulenceGastrointestinal disorders0/131/60/60/7
Influenza like illnessGeneral disorders0/131/60/60/7
Decreased appetiteMetabolism and nutrition disorders0/131/60/61/7
HyponatraemiaMetabolism and nutrition disorders0/131/60/60/7
ConstipationGastrointestinal disorders2/130/60/60/7
Abdominal discomfortGastrointestinal disorders0/130/60/61/7

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Mean55.8 ± 11.363.2 ± 4.551.3 ± 15.460.4 ± 6.657.4 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Female32128
Male1045524
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Hispanic or Latino21104
Not Hispanic or Latino1155728
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American21003
White1146728
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Control (Normal Hepatic Function)Mild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
United States1366732
08

Study locations

3 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70112, United States
09

References and documents

Publications

  • Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022 Jul;61(7):1057-1067. doi: 10.1007/s40262-022-01140-3. Epub 2022 Jun 8. PubMed 35674880 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Sep 2020, 14 months.

Results were first posted in Mar 2023, 2 years 6 months after primary completion.

Of 39 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 14 months is above that.

Counting every sponsor, half of 42 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 7, 2019
StartActual
Jul 22, 2019
Primary completionActual
Sep 22, 2020
CompletionActual
Sep 22, 2020
Results first posted
Mar 24, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03940742
Responsible party
Sponsor
First posted
May 7, 2019
Start date
Jul 22, 2019
Primary completion
Sep 22, 2020
Completion
Sep 22, 2020
Results posted
Mar 24, 2023
Last update
Mar 24, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion